Lundbeck signs $2.5B check for Longboard, seeing blockbuster potential in epilepsy med
Summary: After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is scooping up the biotech for $2.5 billion.
Judo kickstarts with $100M to develop genetic medicines that strike out kidney disease
Summary: Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting the kidney.
New cell therapy biotech emerges with $17M, thymus-targeting therapies
Summary: Cell therapy biotech Tolerance Bio has unveiled with $17.2 million and a mission of targeting immune diseases by stretching and saving the function of a key organ.
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Summary: Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could increase Novo’s dominance over the hot GLP-1 market, reducing competition and increasing prices.
Upstream Raises $255M IPO for Inflammatory Drugs
Summary: CAMP4 Nets $75M for RNA Work Two biotechs set out for the public markets this week, with Upstream Bio raising $255 million for its inflammatory disease work, while CAMP4 Therapeutics picked up $75 million to develop RNA-targeting drugs.
